Endothelial barrier dysfunction underlies chronic inflammatory diseases. In searching for new proteins essential to the human endothelial inflammatory response, we have found that the endosomal GTPase RhoB is up-regulated in response to inflammatory cytokines and expressed in the endothelium of some chronically inflamed tissues. We show that although RhoB and the related RhoA and RhoC play additive and redundant roles in various aspects of endothelial barrier function, RhoB specifically inhibits barrier restoration after acute cell contraction by preventing plasma membrane extension. During barrier restoration, RhoB trafficking is induced between vesicles containing RhoB nanoclusters and plasma membrane protrusions. The Rho GTPase Rac1 controls membrane spreading and stabilizes endothelial barriers. We show that RhoB colocalizes with Rac1 in endosomes and inhibits Rac1 activity and trafficking to the cell border during barrier recovery. Inhibition of endosomal trafficking impairs barrier reformation, whereas induction of Rac1 translocation to the plasma membrane accelerates it. Therefore, RhoB-specific regulation of Rac1 trafficking controls endothelial barrier integrity during inflammation.
In response to infection, tissue damage, or chronic inflammation, cells produce proinflammatory cytokines such as TNF, interleukin-1β (IL-1β), andIFN-γ that have pleiotropic effects on blood vessels surrounding the inflammatory focus. These cytokines trigger a transcriptional program in the endothelium to express proteins necessary for a long-term inflammatory response, including those involved in altering endothelial barrier function. The pathological expression of some of these proteins contributes to the development of inflammatory and thrombotic diseases (Libby, 2002; Compston and Coles, 2008; Khan et al., 2010).
The family of Rho GTPases contains more than 20 members that regulate multiple cellular functions. The founder member of this family, RhoA, is closely related to RhoB and RhoC. These three GTPases are often considered as a RhoA subfamily whose members share 88% amino acid identity and have the potential to regulate common effectors, such as Rho kinases (ROCKs; Ridley, 2013). However, RhoA, RhoB, and RhoC have remarkably different effects on cancer cell migration, which indicate that they also regulate different signaling pathways (Ridley, 2013). The three GTPases in their active state are associated with the plasma membrane, but only RhoB is also localized to the endosomal compartment (Ridley, 2013). In the endothelium, the signaling pathways controlled by the RhoA subfamily are essential for maintaining the barrier integrity, mainly by regulating ROCKs, which drive actomyosin-mediated contractile force generation and modulate cell–cell junctions (Wojciak-Stothard and Ridley, 2002; van Nieuw Amerongen et al., 2007; Vandenbroucke et al., 2008). Despite the importance of this signaling pathway, the relative contribution of each RhoA subfamily member to endothelial barrier function has not been yet characterized. On the other hand, the plasma membrane localization of another Rho GTPase, Rac1, is central to endothelial cell–cell junction remodeling and stabilization (Garcia et al., 2001; Cain et al., 2010; Marcos-Ramiro et al., 2014). Interestingly, Rac1 endosomal internalization and recycling are necessary for the polarized targeting and function of this GTPase to plasma membrane domains, such as circular ruffles in motile tumor cells (Palamidessi et al., 2008). To date, the role of Rac1 intracellular trafficking in the maintenance of endothelial barrier function has not been addressed.
Vascular injury is a hallmark of physiological and pathological inflammation. Prothrombotic proteases and inflammatory mediators induce acute endothelial hyperpermeability that can cause fatal vascular dysfunction (van Nieuw Amerongen et al., 1998; Levi et al., 2004). Among them, thrombin is of particular relevance in chronic inflammation because it can act synergistically with inflammatory cytokines, such as TNF, to modulate endothelial permeability (Tiruppathi et al., 2001) and to activate pathways implicated in the long-term inflammatory response (Levi et al., 2004; Liu et al., 2004). Thrombin is thus determinant in various pathological scenarios, including inflammatory bowel diseases, such as Crohn’s disease (Saibeni et al., 2010). In general, acute endothelial contraction caused by thrombin and other inflammatory factors worsens pathologies related to chronic inflammation (Croce and Libby, 2007; Popović et al., 2012).
Here, in an expression screen for proteins up-regulated in endothelial cells during inflammation, we have found that RhoB protein levels are increased three- to fivefold in response to inflammatory cytokines. RhoB is expressed in small vessels from inflamed intestine or in endothelial beds with high permeability such as those in hepatic sinusoids. We show that RhoB, in conjunction with RhoA and RhoC, plays redundant and additive roles that control various aspects of endothelial barrier function, including ROCK-mediated signaling. In addition to this collaborative role, RhoB is specifically involved in sustaining acute contraction upon thrombin exposure in a context of inflammation. RhoB negatively regulates Rac1 activity and Rac1 intracellular trafficking during barrier recovery. This effect impairs the formation of plasma membrane extensions, inhibits barrier reformation, and makes endothelium persistently exposed to inflammatory cytokines less resistant to mediators that challenge the integrity of the endothelial monolayer.
RhoB expression is increased in response to inflammatory cytokines and in vessels from human inflamed tissues
TNF reduces endothelial barrier integrity, which progressively increases vascular permeability to blood cells and small molecules through mechanisms that are not fully understood (Bradley, 2008). To identify new proteins regulating endothelial barrier function during the inflammatory response, we have combined quantitative PCR (qPCR), proteomics, and Western blotting to search for proteins whose expression is modulated by TNF. A time course of TNF or IL-1β stimulation in human umbilical vein endothelial cells (HUVECs) revealed that RhoB protein levels increase between 4 h and 24 h poststimulation, reaching a maximum fivefold increase for TNF and threefold increase for IL-1β compared with unstimulated cells (Fig. 1, A and B; and Fig. S1 A). No changes were detected in RhoA expression, whereas RhoC expression moderately increased in response to TNF. Primary human dermal microvascular endothelial cells (HDMVECs; Figs. 1 C and S1 B) and human endothelial cell lines (Fig. S1, C and D) also increased RhoB expression in response to TNF. The RhoB increment was moderate in epithelial cell lines (Fig. S1 D). RhoB localizes in endosomes, the cytosol, and the plasma membrane (Sandilands et al., 2004). Immunofluorescence analysis of endogenous RhoB showed that TNF increased RhoB expression mostly in a vesicular, endosomal-like compartment (Fig. 1, B and C). A qPCR analysis of HUVEC mRNA revealed a fourfold increase in RhoB mRNA and no significant changes in RhoA and RhoC mRNA in response to TNF (Fig. 1 D). In the whole Rho family, only the expression of Rnd1 mRNA was also significantly increased in response to TNF, whereas RhoH transcripts were not detected (Fig. S1 E). We quantified the relative expression levels of endogenous RhoA, RhoB, and RhoC proteins and found that they were similar in TNF-stimulated HUVECs (Fig. S1 F). The increase in GTP loading in response to TNF was moderate, with no statistical significance for each of the three Rho proteins (Fig. 1, E and F). The use of a panel of inhibitors suggested that TNF raises the level of RhoB expression mainly through a NF-κB–dependent pathway (Fig. S1, G and H). Therefore, these results indicate that RhoB expression increases upon long-term exposure to inflammatory cytokines. As a result, RhoA, RhoB, and RhoC are similarly expressed and activated in TNF-stimulated endothelial cells.
Immunohistochemical analysis showed that RhoB expression was weak in control umbilical cords (Fig. 2 A), in agreement with our results obtained in vitro from unstimulated HUVECs. RhoB expression was detected in some blood vessels from colon and small intestine tissue of patients with Crohn’s disease (Fig. 2, B–D). Endothelial RhoB expression was localized in vessels in close proximity to fissures, the most inflamed and damaged areas of the tissue (Fig. S2, A–F; and Table S1), whereas vessels in the adjacent areas appeared negative (Fig. S2, A, D, and G–I) as did an isotype-specific control antibody (Fig. S2 J). RhoB-positive vessels were expressing low levels of the NG2 proteoglycan, suggesting that RhoB is highly expressed in postcapillary venules (Fig. 2, E–G). We also found RhoB expression in blood vessels irrigating inflamed ganglia in colon adenopathies associated with tumors (Fig. S2, K and L). We did not detect expression of RhoB in the endothelium of atheroma plaques from the carotid and aorta on in the normal small intestine (unpublished data). The liver parenchyma contains highly permeable vessels called sinusoids. RhoB was highly expressed not only in the sinusoidal endothelium from rejected human liver allografts and livers in advanced stages of hepatitis B virus infection but also in control donors (Fig. 2, H and I; and Table S1). Therefore, high levels of RhoB protein expression were detected in inflamed small blood vessels in human intestine and liver sinusoids, suggesting that RhoB protein levels are higher in endothelial beds with diminished barrier function.
A screening of endothelial barrier function reveals additive, redundant, and negative roles of the RhoA-subfamily proteins in unstimulated and TNF-stimulated HUVECs
The involvement of the Rho pathway in human cell barrier function has most often been addressed by inhibiting the entire RhoA protein subfamily or their common downstream effectors (McKenzie and Ridley, 2007; Fernández-Martín et al., 2012). Hence, we aimed to determine whether up-regulated RhoB plays a specific role in different barrier properties of human endothelial cells during inflammation (summarized in Table 1) by silencing the expression of each RhoA subfamily member with siRNA oligonucleotides (Fig. S3, A–D). Single and double Rho gene silencing induced expression changes in the remaining Rho proteins. RhoA depletion increased the expression of RhoB and RhoC by 2- to 2.5-fold, whereas single knockdown of RhoB increased RhoA and RhoC expression by 1.5- to 2-fold. Knockdown of RhoC moderately increased RhoA expression in TNF-stimulated and unstimulated cells, whereas reduced RhoB expression by 30% only in unstimulated HUVECs. Double reduction of Rho proteins caused a stronger compensatory increase in the expression of the remaining GTPases (Fig. S3, B and C). This suggests that RhoA, RhoB, and RhoC play additive or redundant roles in endothelial cells, which features mechanisms to modulate their expression and compensate for each other´s function. Indeed, individual depletion of RhoB and RhoC, but not RhoA, as well as the double Rho knockdown, decreased barrier function in unstimulated HUVECs, but this decrease was stronger upon triple Rho depletion (Fig. S3 E). These results suggest that RhoA, RhoB, and RhoC play additive roles in regulating constitutive endothelial barrier function. Electric cell substrate impedance sensing assays, which measures transendothelial electric resistance (TEER), and transwell permeability assays indicated that RhoC plays a predominant role in maintaining the integrity of the endothelial barrier in the absence of inflammatory stimuli (Fig. S3, E and F). We then examined the relative contribution of each Rho protein to the regulation of F-actin. Single Rho knockdown was not sufficient to reduce F-actin levels. In contrast, cells expressing only RhoB or RhoA, as well as cells depleted of the three GTPases, reduced them (Fig. S3, G and H). Collectively, these results indicate that these three GTPases play redundant roles in the regulation of F-actin. It is of note that cells expressing only RhoC had higher levels of F-actin, suggesting that RhoC expression is sufficient to mediate actin polymerization.
We investigated the role of RhoB in the endothelial barrier function of cells exposed to TNF. Single Rho protein depletion had no effect on permeability in cells stimulated with TNF between 7 and 24 h (Fig. 3, A and B). The F-actin levels and the T cell transendothelial migration were neither affected by individual Rho knockdown in TNF-stimulated HUVECs (Fig. S4, A–C). Discontinuous adherens junctions connecting actin stress fibers from adjacent cells regulate intercellular tension and are increased in response to TNF (Millán et al., 2010; Huveneers et al., 2012). The single reduction of each Rho protein had no apparent effect on the morphology of adherens junctions, whereas triple Rho knockdown turned them into linear junctions interspersed with big gaps (Fig. S4, A and B). Therefore, TEER and F-actin levels were reduced in TNF-stimulated cells simultaneously silenced for the three Rho GTPases, although this could not be attributed to a specific effect on TNF-mediated signaling because it was also observed before the TNF exposure (Fig. S3, G and H). However, the inhibition of ROCK, the main Rho downstream effector that controls actomyosin levels, did not prevent the reduction in TEER in TNF-stimulated cells (Fig. 3 A) as we had previously observed (McKenzie and Ridley, 2007; Fernández-Martín et al., 2012). This suggests that the RhoA GTPase subfamily has no significant role in long-term endothelial barrier disruption in response to TNF.
RhoB sustains acute contraction and delays endothelial barrier recovery in TNF-stimulated HUVECs
Inflammation and coagulation influence each other in chronic inflammatory pathologies such as Crohn’s disease, ulcerative colitis, and multiple sclerosis (Scaldaferri et al., 2011; Roshanisefat et al., 2014). Thrombin-mediated activation of protease-activated receptors is a paradigm of acute Rho-controlled actomyosin-dependent contraction that disrupts endothelial integrity and causes vascular dysfunction in a range of proinflammatory diseases (Croce and Libby, 2007; Borissoff et al., 2009). Thus, we next investigated whether TNF–up-regulated RhoB expression contributes to acute barrier disruption induced by thrombin in an inflammatory context. The barrier function of TNF-pretreated, single siRNA–transfected HUVECs was analyzed after thrombin stimulation. Before thrombin, no significant changes in TEER were observed in these cells (Fig. 3 A). Thrombin induced a rapid and acute decrease in TEER, followed by a slower recovery to initial values of resistance (Fig. 3 C, left graph). Control siRNA or siRNA targeting RhoA and RhoC had no major effect on TEER. RhoB was silenced with two individual siRNAs, as well as with a pool of four different and specific RhoB siRNAs designed to reduce off-target effects (Fig. S3, A–D). The three sets of RhoB siRNA inhibited the initial reduction of TEER 30 min after thrombin stimulation (maximum contraction) and significantly shortened the subsequent monolayer recovery time, quantified by measuring TEER recovery 72 min after thrombin stimulation (Fig. 3, C [right] and D; and Fig. S3, A–D). This was similar to the effect that we and others had observed by ROCK inhibition (Fig. 3 C; Kawkitinarong et al., 2004; Fernández-Martín et al., 2012), although Y27632 had a stronger effect on initial contraction. RhoB-depleted cells also had reduced permeability when analyzed by transwell permeability assays during the period of time between acute contraction and barrier recovery (Fig. 3 E). RhoB knockdown increased cell–cell junction integrity, which was addressed by localizing β-catenin after thrombin stimulation (Fig. 3 F, right graph). RhoB knockdown had a specific but milder effect on endothelial barrier reformation in HUVECs not previously treated with TNF and, therefore, with lower levels of RhoB protein (Fig. 3 G). Finally, in HDMVECs, single Rho knockdown induced a moderate decrease in acute contraction, whereas barrier recovery was also accelerated by RhoB depletion and at less extent, by RhoC depletion (Fig. 3 H and Fig. S3, A and D). HDMVEC barrier reformation was increased upon RhoB knockdown when analyzed by confocal analysis of cell–cell junction integrity (Fig. 3 I), indicating that RhoB also plays a specific role in prolonging thrombin-induced barrier disruption in microvascular endothelial cells.
Thrombin stimulation activated RhoA, RhoB, and RhoC with comparable kinetics in HUVECs pretreated with TNF (Fig. 4, A and B). Because expression levels were also similar (Fig. S1 F), we hypothesized that RhoB specificity on prolonging cell contraction could be caused by the differential regulation of downstream signaling pathways involved in this process. Active Rho can increase myosin light chain (MLC) phosphorylation through ROCK activation (Riento and Ridley, 2003). This promotes nonmuscle myosin II isoforms to interact with F-actin and to increase actomyosin contractility. Depletion of RhoA, but not RhoB, reduced MLC phosphorylation 2 min after thrombin stimulation (Fig. 4, C and D). Paxillin is a scaffolding protein that regulates focal adhesion (FA) stability and becomes phosphorylated upon interaction with other FA components, including FA kinase, reported to be essential for endothelial barrier restoration after thrombin stimulation (Knezevic et al., 2009). Single RhoA and RhoB knockdown similarly reduced paxillin phosphorylation in Tyr-31, which suggested no selective role for RhoB in regulating this protein (Fig. 4, C and E). These results suggest that RhoB’s specific role in endothelial barrier recovery does not involve signaling to MLC and paxillin and that partial inhibition of MLC activation is not sufficient to prevent thrombin-induced contraction.
RhoB prevents endothelial plasma membrane extension after acute contraction
We observed that the expression of a constitutive active mutant RhoB-V14 had no effect on cell–cell junction integrity even though cell-spread area was significantly reduced (Fig. 5 A). This led us to hypothesize that the role of RhoB in thrombin-mediated endothelial remodeling may be independent of the reannealing of cell–cell junctions. Indeed, the kinetics of thrombin-induced contraction and subsequent spreading in TNF-pretreated subconfluent HUVECs were consistent with those of barrier disruption and reformation in confluent cells, indicating that cell contraction and recovery are independent of the cell–cell junctions (Figs. 3 C and 5 B). Confocal analysis revealed that RhoB knockdown slightly increased cell area of subconfluent HUVECs before thrombin stimulation and clearly accelerated cell respreading after thrombin-mediated contraction (Fig. 5 C). 60 min after thrombin stimulation, RhoB-depleted cells recovered their initial spreading area, whereas siControl cells had only 60% of their area before stimulation (Fig. 5 C). In contrast, RhoB-V14 expression reduced cell respreading (Fig. 5 D), suggesting that RhoB negatively regulates the membrane extension that follows acute contraction. A similar increase in cell area was observed in RhoB-depleted subconfluent HDMVECs at the time of cell respreading (Fig. 5 E).
Time-lapse confocal analysis of GFP-RhoB revealed that the number of RhoB-positive vesicles moving between an endosomal-like perinuclear compartment and the plasma membrane more than doubled during membrane reextension after thrombin-induced contraction, compared with cells before contraction (Fig. 6, A–C; and Videos 1 and 2). This increase was detected in both directions, from the perinuclear compartment toward the plasma membrane (Fig. 6 B) as well as for vesicles that emerge from the plasma membrane and follow inward movement (Fig. 6 C). In addition, the analysis of endogenous RhoB distribution by superresolution microscopy revealed that RhoB was not evenly distributed but formed nanoclusters in the endosomal vesicles (Fig. 6 D), which were modestly reduced in response to thrombin (Fig. 6 E). To identify the intracellular localization of RhoB, we analyzed the distribution of endogenous RhoB with respect to different endosomal markers. RhoB has been localized in an early endosomal compartment (Fernandez-Borja et al., 2005; Kroon et al., 2013). TNF-stimulated HUVECs were loaded with transferrin-TRITC for 5 min before performing a time course of thrombin stimulation. A small fraction of RhoB vesicles overlapped with transferrin suggesting a partial localization of RhoB in early endosomes (Fig. 6 F and not depicted). This was confirmed by colocalization analysis in cells expressing the early endosomal GFP-Rab5, in which some vesicles overlapped with RhoB at any time of thrombin stimulation (Fig. 6 F and not depicted). The partial overlap between RhoB and transferrin was reduced in cells stimulated with thrombin and simultaneously loaded with transferrin for 1.2 h, which suggests that RhoB does not significantly localize in an endosomal-recycling compartment during barrier recovery (Fig. 6 F). RhoB colocalization with recycling GFP-Rab11 was also minor at any time of thrombin stimulation (Fig. S5 A and not depicted). Similarly, the colocalization of RhoB vesicles with the fast-recycling Rab4 and the protein epsin homology domain 1 (EHD-1), which regulates specific trafficking pathways in the recycling system (Goldenring, 2015), was negligible (Fig. S5 A). In contrast, RhoB perinuclear clusters and vesicles colocalized with the late endosomal marker Rab7, suggesting that RhoB distributes along the endocytic route between early and late endosomes, but mainly in this latter compartment, as previously described for epithelial cell lines (Wherlock et al., 2004).
RhoB negatively regulates Rac1 trafficking from the endosomal compartment to the plasma membrane
The Rho GTPase Rac1 plays a central role in regulating plasma membrane extension (Price et al., 1998) and endothelial permeability and cell–cell junction stabilization (Daneshjou et al., 2015). We investigated whether RhoB regulates Rac1-mediated cell spreading. Exogenous expression of Rac1 was sufficient to induce membrane extensions and increase the cell-spread area HEK293 cells. Interestingly, coexpression of RhoB-V14 impaired Rac1-induced protrusions in cells expressing similar levels of exogenous Rac1 (Fig. S5 B). Thus, active RhoB impairs the plasma membrane extension after thrombin stimulation, but also upon Rac1 overexpression. The extension of the plasma membrane during cell migration requires Rac trafficking between the plasma membrane and a Rab5-positive endosomal compartment, in which Rac encounters and recycles with guanine nucleotide exchange factors toward the plasma membrane to form F-actin–mediated protrusions (Palamidessi et al., 2008). We analyzed the distribution of Rac1 in endothelial cells and found it to be localized at the plasma membrane and in internal vesicular clusters (Fig. 7 A). Expression of constitutively active RhoB-V14 significantly reduced Rac1 localization in the plasma membrane, even in cells that were properly spread and adhered to the substrate (Fig. 7 A). In contrast, reduction of RhoB expression increased Rac1 localization at cell borders (Fig. 7 B). Moreover, Rac1 and RhoB-V14 clearly colocalized in a perinuclear vesicular compartment positive for Rab7 (Fig. 7, C and D) and in a compartment positive for Rab5 (Fig. 7, C and E). The localization of active RhoB-V14 in Rab5-positive endosomes increased with respect to exogenous or endogenous RhoB (Figs. 6 F and 7 E). Endogenous RhoB staining also overlapped with Rac1 in an intracellular compartment in confluent HUVECs (Fig. 7 F) and in HDMVECs (Fig. S5 C) pretreated with TNF. During barrier reformation after thrombin stimulation, Rac1 and RhoB partially colocalized in vesicles, but not in lamellipodial-like extensions (Fig. 7 F). Therefore, RhoB activity reduces Rac1 presence at the cell border and favors Rac1 intracellular localization.
However, superresolution confocal microscopy suggested that Rac1 and RhoB accumulate in different domains in intracellular vesicles (Fig. 7 G). Accordingly, no association was detected between Rac1 and RhoB in coimmunoprecipitation experiments and in the pull-down assays performed to analyze Rac1 and RhoB activity (unpublished data). We then investigated whether RhoB and Rac1 could be in proximity and therefore establish transient but undetectable interactions. We generated a construct of RhoB conjugated from its N-terminal domain to the mutant of biotin-ligase BirA, which adds biotin to proteins in its proximity, and performed BioID assays (Fig. 7 H; Roux et al., 2012). GFP-Rac1 coexpressed with RhoB-BirA was detected in pull-down assays performed with neutravidin to purify biotinylated proteins (Fig. S5 D). Exogenous biotin was required for GFP-Rac1 biotinylation, whereas GFP alone was not biotinylated (Fig. S5 E). Overexpression of RhoB-BirA induced a reduction of GFP-Rac1 expression compared with cells expressing only GFP-Rac1 (Fig. S5 D and Fig. 7 H). We then adopted a complementary strategy and immunoprecipitated Rac1 in the presence or absence of BirA-RhoB. Cells expressing BirA-RhoB induced biotinylation of several proteins, which were detected by blotting with streptavidin conjugated to peroxidase (Fig. 7 H). At least four biotinylated proteins were found in the GFP-Rac1 immunoprecipitates (Fig. 7 H, asterisks). Two of these proteins were coincident with those detected by Western blot using anti-Rac1 antibody, which corresponded to the molecular weights of GFP-Rac1 and endogenous Rac1, which coimmunoprecipitated with GFP-Rac1 (Fig. 7 H).
Consistent with the role of RhoB in Rac1 localization, time-lapse confocal microscopy revealed that RhoB knockdown reduced the number of Rac1 vesicles moving toward and away from the plasma membrane and induced the accumulation of Rac1 at the periphery (Fig. 7, I and J; and Videos 3 and 4). Together, these results indicate that active RhoB transiently colocalizes with and retains Rac1 in an endosomal compartment, preventing it localizing to the plasma membrane.
RhoB inhibits endothelial barrier restoration by controlling Rac1 activity and trafficking
Simultaneously with RhoA and RhoB activation, Rac1 activity decreases within the first minutes of thrombin stimulation and subsequently recovers (Fig. 8 A). Pull-down assays during a time course of thrombin stimulation showed an increase in Rac1 activity in RhoB-depleted HUVECs with respect to control cells at the time of cell respreading (Fig. 8 A). Rac1 activity did not change in RhoA-depleted cells (Fig. 8 B). Transient inhibition of Rac activity with NSC23766 during the time of barrier recovery abolished the effect of RhoB siRNA (Fig. 8, C and D), suggesting that Rac mediates the role of RhoB in sustaining cell contraction in endothelial monolayers. Next, we addressed whether Rac1 trafficking is involved in barrier restoration. Brefeldin A is a lactone antibiotic that inhibits anterograde intracellular transport and induces tubulation of the endosomal system (Lippincott-Schwartz et al., 1991), monensin is a ionophore that increases the pH of acidic endosomal vesicles and blocks their transport (Chapman and Munro, 1994), and dynasore impairs vesicle endocytosis and recycling by inhibiting dynamin-2, a GTPase involved in clathrin-coated vesicle formation (Macia et al., 2006). We found that brefeldin A, monensin, and dynasore decreased barrier reformation and caused intracellular accumulation of Rac1 (Fig. 9, A, B, and E). In addition, brefeldin A reduced the movement of Rac1-positive intracellular vesicles (Fig. S5, F and G; and Videos 5 and 6). Conversely, hepatocyte growth factor (HGF) induces Rac1 translocation from the Rab5 compartment to the plasma membrane in nonendothelial cells (Palamidessi et al., 2008). Exposure of thrombin-stimulated endothelial cells to HGF at the initiation of monolayer recovery increased Rac1 translocation to the plasma membrane and, accordingly, accelerated barrier function recovery (Birukova et al., 2007; Fig. 9, C-E), similar to the effect of RhoB knockdown. Together, our results indicate that RhoB negatively regulates the endothelial membrane extensions required for barrier reformation, which are controlled by Rac1 trafficking.
Finally, we had previously shown a milder effect of RhoB siRNA on endothelial barrier recovery in the absence of long-term TNF stimulation, in which RhoB is expressed at low levels (Fig. S5 A). NSC23766 moderately delayed barrier reformation in unstimulated cells but caused strong and sustained inhibition of barrier reformation at least 4 h after thrombin stimulation in TNF-pretreated cells (Fig. 9 F). These results suggest that RhoB and Rac1 contribute to endothelial barrier recovery primarily in an inflammatory context.
To investigate the molecular mechanisms mediating endothelial barrier dysfunction, we searched for new proteins whose expression is modulated by TNF. We found that TNF and IL-1β increased RhoB mRNA and protein expression in HDMVECs and HUVECs, which is comparable to what was recently reported in HUVECs (Kroon et al., 2013). In addition, RhoB is highly expressed in some vessels from chronically inflamed tissues, such as those in lesions from patients with Crohn’s disease, and in leaky and specialized vessels, such as hepatic sinusoids. RhoB belongs to the RhoA subfamily, which regulates common effectors that are potential targets for treating proinflammatory and prothrombotic diseases and ameliorating endothelial dysfunction (Shi and Wei, 2013). For this reason, we undertook a detailed analysis of the role of each subfamily member in this regulation in human primary endothelial cells. Our functional analyses by transient gene silencing reveal first that RhoA, RhoB, and RhoC play additive roles in maintaining homeostatic barrier function and junction distribution and redundant or compensatory roles in regulating F-actin levels. The additive roles of RhoA and RhoB in endothelial barrier function have also been observed by expressing dominant-negative (DN) forms of RhoA and RhoB (Wojciak-Stothard et al., 2012). Single expression of the DN mutant of RhoA significantly inhibited the increase in pulmonary endothelial permeability noted under hypoxic conditions, whereas no significant effect was detected upon expression of DN RhoB. Coexpression of both DN mutants increased their inhibitory effect, suggesting that RhoB cooperates with RhoA in controlling endothelial barrier disruption during hypoxia (Wojciak-Stothard et al., 2012). DN Rho proteins inhibit endogenous Rho proteins by sequestering upstream GTP exchange factors, so their DN effect is extended to those Rho proteins that share these activators (Feig, 1999). Hence, their specificity with respect to the other two members of the family may be reduced compared with gene-silencing–based strategies. Our data indicate that among those additive effects, RhoC plays a main role in controlling constitutive endothelial barrier function whereas RhoB seems to have a predominant role in mediating acute contraction in endothelial cells exposed to inflammatory mediators. The analyses of a knockout mouse model of RhoB and the gene silencing of RhoC in human endothelial cells have previously shown the importance of RhoB and RhoC for other endothelial functions related to barrier function such as angiogenesis (Gerald et al., 2013; Hoeppner et al., 2015), whereas the study of the vascular-specific RhoA knockout mouse indicate that this GTPase is essential for mediating the permeability increase in response to histamine (Mikelis et al., 2015). However, no comparative studies of the relative expression and contribution of other RhoA subfamily members have been reported in these studies.
Thrombotic factors can cause endothelial contraction leading to a disruption of vascular integrity during inflammation (Beckers et al., 2010). Whereas contraction can be partially inhibited by inhibitors that target the common downstream effector ROCK (Komarova et al., 2007; Fernández-Martín et al., 2012), we have identified a novel and specific function for RhoB as a negative regulator of barrier reformation through the control of Rac1 localization and activity. This negative regulation occurs in cytokine-pretreated vascular and microvascular endothelial cells, but it is also detected in endothelial cells that are not pretreated with cytokines in which the effect of RhoB siRNA is milder than in TNF-stimulated cells, consistent with the relatively low level of expression of RhoB in the absence of inflammatory stimulation. Therefore, on the one hand, RhoB has similar roles to those of RhoA and RhoC, for instance, in regulating F-actin, whereas RhoB specifically mediates endothelial barrier reformation and controls Rac1 intracellular trafficking. This dual role might reflect the fact that RhoB is the only member of this subfamily that undergoes alternative lipid modifications in its C-terminal domain. Similar to RhoA and RhoC, a subset of RhoB is geranylgeranylated and localizes at the plasma membrane in its active form, whereas another subset of RhoB molecules, but not of RhoA and RhoC molecules, is isoprenylated and palmitoylated, which specifically localizes that GTPase at the endosomal compartment (Wheeler and Ridley, 2004; Pérez-Sala et al., 2009).
Rac1 targeting to the cell border from an endosomal compartment was found to be necessary to form actin-mediated plasma-membrane protrusions during cell migration, and HGF stimulated this Rac translocation (Palamidessi et al., 2008). Interestingly, we and others have found that HGF accelerates endothelial barrier recovery (Birukova et al., 2007, 2008), which, as we show here, is associated with increased Rac1 localization at the plasma membrane. These data indicate that Rac1 trafficking in the endothelium after thrombin-mediated acute contraction is comparable to Rac1 translocation in migrating cells and is regulated by endosomal RhoB. RhoB also regulates Rac1 negatively in cancer cell invasion (Bousquet et al., 2009) and positively in platelet-derived growth factor stimulation (Huang et al., 2011). RhoB has been proposed to link endosomal vesicles to actin filaments through its effector formins mDia1 and mDia2 (Sandilands et al., 2004; Fernandez-Borja et al., 2005; Wallar et al., 2007). Constitutively active RhoB or mDia mutants reduce the velocity of intracellular vesicles, probably by increasing the association of endosomal carriers with actin filaments (Fernandez-Borja et al., 2005; Wallar et al., 2007). We have found that RhoB depletion increases Rac1 at cell borders and reduces the trafficking of remaining Rac1 vesicles, suggesting that RhoB controls Rac1 vesicular movement toward the cell border and, hence, toward nascent cell–cell junctions. Active RhoB also accumulates with Rac1 in a Rab7-positive endosomal compartment, which suggests that RhoB activity may not only control vesicular dynamics but also divert recycling Rac1 to a late-endosomal compartment, thereby delaying the return to the plasma membrane (Fig. 9 G).
In an inflammatory context, Rac1 promotes extension of ventral lamellipodia to repair microwounds caused by adhered leukocytes undergoing diapedesis (Martinelli et al., 2013). However, the role of vesicular trafficking and Rac1 recycling has not yet been addressed for this type of membrane extension. The parallels between the signaling machinery mediating membrane extension during migration and barrier formation can be also found upstream of Rac1. Platelet-derived growth factor or HGF induces Rac1 translocation to endosomes where this GTPase encounters the GTP exchange factor Tiam1 during recycling to form actin-based migratory protrusions. In the endothelium, Tiam1 contributes to Rac1 activation in response to various barrier-stabilizing mediators (Schlegel and Waschke, 2014). Indeed, a close connection between lamellipodia and maturation of cell–cell junctions has recently been described (Abu Taha et al., 2014).
The effect of Rac inhibition on barrier reformation between TNF-treated and resting endothelial cells is markedly different. Other researchers have reported that TNF causes a striking delay in endothelial barrier formation after thrombin-induced contraction (Paria et al., 2004). We propose that endothelial barrier disruption in response to long-term exposure to inflammatory cytokines such as TNF involves not only an increase in permeability to cells and small molecules but also a decrease in the “robustness” of the endothelial monolayer by reducing the ability of endothelial cells to reform the monolayer upon disruption. This would make the endothelium more prone to disruption by injury or edemagenic and coagulatory challenges that arise in different inflammatory contexts, particularly in chronic diseases such as Crohn’s or hepatitis. Targeting negative regulators of barrier formation expressed in such contexts such as RhoB may help preserve endothelial and vascular integrity in inflammatory pathologies.
Materials and methods
Mouse monoclonal anti–VE-cadherin (catalog number 610252), mouse anti-Paxillin (catalog number 610051), and mouse anti-Rac1 (catalog number 610650) were purchased from BD. Rabbit anti–ICAM-1 (Sc-7891), rabbit anti-MLC (sc-15370), rabbit anti–ERK-1/2 (sc-94), mouse anti-RhoA (sc-418), and rabbit anti-RhoB (sc-180) for Western blot, mouse anti-RhoB (sc-8048) for immunofluorescence, and rabbit anti-RhoA/C (sc-179) were purchased from Santa Cruz Biotechnology, Inc. Rabbit anti-RhoC (D40E4) antibody was obtained from Cell Signaling Technology. Rabbit anti–β-catenin (C-2206) antibody was obtained from Sigma-Aldrich. Rabbit anti–p(T18/S19)MLC (44-260G) and anti–p(Y31) paxillin (44-720G) were obtained from Invitrogen. Goat anti–VCAM-1 (BBA19) was purchased from R&D Systems. Rat anti-HA (11867423001, clone 3F10), mouse anti-c-myc (11667149001, clone 9E10), and mouse anti-GFP (11814460001) were obtained from Roche. Phalloidin-TRITC (P-1951) was obtained from Sigma-Aldrich. Anti-IgG mouse ATTO-647N was obtained from Sigma-Aldrich (50185). Alexa Fluor 647 Phalloidin (A-22287) and To-Pro-3(T-3605) were obtained from Invitrogen. Rac1 inhibitor NSC23766 (553502), dynamin inhibitor I (dynasore; CAS 304448–55-3), and monensin (475895) were purchased from EMD Millipore. Brefeldin A (20350–15-6) was purchased from Sigma-Aldrich. Human HGF (PHG0254) was purchased from Gibco. Thrombin from human plasma (T6884) was purchased from Sigma-Aldrich. Recombinant human TNF and IL-1β was obtained from R&D Systems.
Plasmids, siRNA, and RT-qPCR analysis
Plasmid coding for HA-RhoB was from the UMR cDNA resource center (University Missouri-Rolla). Plasmids coding for HA-RhoB-V14 and GFP-RhoB were a gift from D. Pérez-Sala (Centro de Investigaciones Biolgicas, Madrid, Spain)(Centro de Investigaciones Biológicas, Madrid, Spain). To obtain a plasmid to express BirA-RhoB, a two-step procedure was followed. The sequence coding for GFP in the pEGFP-C1 expression vector was substituted by the BirA sequence. Then, the RhoB sequence was amplified by PCR and cloned between BglII and BamH1 restriction sites in the multicloning site. Plasmid coding for mCherry-Rac1 was a gift from F. Martín-Belmonte (Centro de Biología Molecular Severo Ochoa, Madrid, Spain). Plasmid from GFP-Rac1 was obtained from G. Bokoch (Scripps Research Institute, La Jolla, CA) through Addgene. Plasmid coding for GFP-Rab4 was from Gia Voeltz through Addgene. Plasmid coding for GFP-Rab5 was a gift from R. Puertollano (National Institutes of Health, Bethesda, MD). Plasmids coding for GFP-Rab7 and GFP-Rab11 were a gift of M.A. Alonso (Centro de Biología Molecular Severo Ochoa, Madrid, Spain). Plasmids coding for GFP(emerald)-Rab7 and GFP(emerald)-Rab5 were also used and were obtained from M. Davidson (Florida State University, Tallahassee, FL) through Addgene. The following siRNA oligonuceotides were obtained from the predesigned siGenome collection of Dharmacon (Vega et al., 2011): siControl1: nontargeting control, D-001210-01, 5′-UAGCGACUAAACACAICAA-3′; siControl2: nontargeting control, D-001810-03, 5′-AUGUAUUGGCCUGUAUUAG-3′; siRhoA1: D-003860-01, 5′-AUGGAAAGCAGGUAGAGUU-3′; siRhoA2: D-003860-02, 5′-GAACUAUGUGGCAGAUAUC-3′; siRhoB1: D-008395-07, 5′-GCAUCCAAGCCUACGACUA-3′; siRhoB2: D-008395-09, 5′-CAUCCAAGCCUACGACUAC-3′, or D-008395-08, 5′-ACACCGACGUCAUUCUCAU-3′; siRhoC1: D008555-02, 5′-AUAAGAAGGACCUGAGGCA-3′; siRhoC2: D008555-03. ON-TARGETplus SMART pool siRNA, consisting of a pool of four siRNAs, was also from Dharmacon and consisted in the following sequences: siControlpool D-001810-10, 5′-UGGUUUACAUGUCGACUAA-3′, 5′-UGGUUUACAUGUUGUGUGA-3′, 5′-UGGUUUACAUGUUUUCUGA-3′, and 5′-UGGUUUACAUGUUUUCCUA-3′; SiRhoBpool L-008395: J008395-11, 5′-GCAUCCAAGCCUACGACUA-3′; J008395-12, 5′-CAGAACGGCUGCAUCAACU-3′; J008395-13, 5′-CGACGAGCAUGUCCGCACA-3′; and J008395-14, 5′-AAGCACUUCUGUCCCAAUG-3′. siRNA oligonucleotides were transfected with oligofectamine (Invitrogen; Fernández-Martín et al., 2012). Oligonucleotides for qPCR were from Sigma-Aldrich. One microgram of RNA from HUVECs was subjected to reverse transcription with the High Capacity RNA-cDNA kit (Applied Biosystems). RT-qPCR was performed from the resulting cDNA in a thermocycler CFX 384 (Bio-Rad) using the SsoFast EvaGreen Supermix (Bio-Rad) and the forward and reverse primers, previously designed with Probefinder software (Roche), described in Table S2 and previously used in T cells (Bhavsar et al., 2013). Parallel qPCR for the reference genes β-actin and GADPH was performed to normalize data from each point of stimulation. Triplicates from all the samples were run in parallel with non–reverse transcription controls for all the targets that yielded no detectable amplification. Unless indicated otherwise, the quantification cycle (Cq) values were in the 20–24 range, which indicates medium to high levels of these transcripts. Melting curves showed specific amplification in all cases except for RhoH. RhoH can be amplified with the same pair of oligonucleotides in T cell lines (Bhavsar et al., 2013). Relative quantification was performed with the software GenEx taking into account for corrections the efficiency of each pair of primers, the technical triplicates, and the contamination with genomic DNA, which was negligible. The relative quantification (2−ΔCq) was made with respect to the expression at time 0 of TNF stimulation. Subsequently, these values were normalized again with respect a mean of the values of the reference genes. To do this, the stability of the candidate reference genes was evaluated with geNorm and Normfinder algorithms within Genex, and a combination of the two most stable was chosen to normalize the results.
Cell culture and transfection
HeLa and HepG2 cells were obtained from the American Type Culture Collection. These cells, EA.hy.926 cells and HBMEC cells were grown in DMEM supplemented with 10% FBS in an atmosphere of 5% CO2/95% air. EA.hy.926 cells were a gift from C.J.S. Edgell (University of North Carolina, Chapel Hill, NC), and HBMECs were a gift from B. Weksler (Cornell University, Ithaca, NY). Adult HDMVECs and the CADMEC growth medium were from Tebu-Bio. HUVECs were from Lonza. For siRNA transfection, HUVECs and HDMVECs were plated at subconfluence (105 cells on each well of a six-well dish) in EBM-2 medium (Lonza) with no antibiotics. The next day, cells were transfected by mixing 4 µl of oligofectamine (Invitrogen) with siRNA to a final concentration of 100 nM. At 24 h after transfection, cells were trypsinized and plated at confluence onto different dishes for parallel assays, such as permeability, adhesion, immunofluorescence or Western blotting (Aranda et al., 2013). Assays were performed 72 h after transfection. T-lymphoblasts were prepared from isolated human peripheral blood mononuclear cells. Nonadherent peripheral blood mononuclear cells were stimulated with 0.5% phytohemagglutinin for 48 h and maintained in culture medium supplemented with interleukin-2 as previously described (Reglero-Real et al., 2014). T lymphoblasts were used in experiments after culturing for 7–12 d.
Pull-down assays to detect Rho activity
HUVECs were transfected with the indicated siRNAs. After 72 h, cells were lysed and subjected to pull-down assays to analyze active, GTP-loaded RhoGTPases as previously described (Cernuda-Morollón et al., 2010; Fernández-Martín et al., 2012). In brief, cell lysates were incubated at 4°C in assay buffer with 10 µg GST-fusion proteins immobilized on GST-Sepharose beads. Active RhoA, RhoB, and RhoC were detected by pull-down with GST-rhotekin-RBD and active Rac1 with GST-PAK-PBD. Then, a fraction of the initial postnuclear supernatants and the final GST pull-down samples were subjected to SDS-PAGE in 12% acrylamide gels under reducing conditions and transferred to Immobilon-P membranes (EMD Millipore). After blocking with 5% nonfat dry milk, 0.05% (vol/vol) Tween 20 in PBS, the membranes were incubated with the indicated antibodies, washed with PBS + 0.05% Tween 20, and incubated with the appropriate secondary antibodies coupled to HRP. After subsequent extensive washes, the membranes were developed using an enhanced chemiluminescence Western blotting kit (ECL; GE Healthcare).
The expression vectors coding for BirA-RhoB and GFP-Rac were transfected in HEK293 cells with PEI (Sigma-Aldrich) 48 h before the assays. Cells were incubated with 50 µM biotin for 24 h, lysed and subjected to pull-down assay of biotinylated proteins with Neutravidin-Agarose (Thermo Fisher Scientific) as previously described (Roux et al., 2012; Rodríguez-Fraticelli et al., 2015;). Alternatively, cells were lysed in 25 mM Tris-HCl, pH 7.4, 1% Triton X-100, 150 mM NaCl, and 2 mM EDTA buffer containing protease inhibitors for 1 h at 4°C. After preclearing the postnuclear supernatant for 1 h with isotype-specific control immunoglobulin (Sigma-Aldrich) conjugated to protein G–Sepharose (Sigma-Aldrich), GFP-Rac was immunoprecipitated with specific anti-GFP antibodies (Roche) conjugated to protein G–Sepharose for 12 h. In parallel, a control immunoprecipitation with the isotype-specific control immunoglobulin was performed. After extensive washes with the lysis buffer, immunoprecipitates were analyzed by Western blot with anti-Rac1 antibodies and by blot with streptavidin-peroxidase (Thermo Fisher Scientific).
Endothelial permeability and leukocyte transendothelial migration assays
Permeability assays were performed as previously described (Wójciak-Stothard et al., 2001; McKenzie and Ridley, 2007). HUVECs were plated at confluence onto fibronectin-coated transwells in growth medium. After 24 h they were rinsed and stimulated or not for 20 h with TNF (10 ng/ml in growth medium) added to the top chamber of the transwell. FITC-dextran (Mr 42,000; Sigma-Aldrich) was applied apically at 0.1 mg/ml and allowed to equilibrate for 60 min before a sample of the medium was removed from the lower chamber to measure fluorescence in the Fusion α-FS fluorimeter. TEER assays with an electric cell-substrate impedance sensing system (ECIS 1600R; Applied Biophysics; Tiruppathi et al., 1992) were performed as described (Fernández-Martín et al., 2012; Aranda et al., 2013). TEER decrease during contraction and the subsequent recovery was expressed as the percentage of the difference in resistance detected between wells containing endothelial cells before and after stimulation with thrombin at the time of maximum contraction (1 U/ml thrombin in HUVECs, 0.5 h stimulation) or (10 U/ml thrombin in HDMVEC, 1 h stimulation). For transendothelial migration assays, HUVECs previously transfected with the indicated siRNAs were seeded at confluence on transwells with 5-µm-diameter pores for 48 h. T-lymphoblasts were labeled with 0.5 µm 2′,7′,-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (Molecular Probes) in serum-free medium for 20 min, washed with medium containing 10% FBS, and added to the top chamber of the HUVEC-containing transwells. 50 µg/ml SDF-1α was added to the bottom chamber as chemo attractant. After 2 h of incubation at 37°C, transmigrated T-lymphoblasts were harvested from the bottom chamber and fluorescence was measured in a Fusion α-FS fluorimeter (PerkinElmer) with a 480 nm filter. P values were calculated using Student’s t test on a minimum of three experiments with duplicates.
Confocal and time-lapse microscopy
For confocal microscopy, cells were fixed with 4% paraformaldehyde for 20 min, blocked with TBS (25 mM Tris, pH 7.4, and 150 mM NaCl) plus 10 mM Glycine for 10 min, permeabilized for 5 min with TBS containing 0.2% Triton X-100 at 4°C, blocked with TBS containing 3% BSA for 30 min and incubated at 37°C with primary antibodies then fluorophore-conjugated secondary antibodies and 1 µg/ml TRITC/FITC/Alexa Fluor 647–labeled phalloidin. Secondary antibodies fluorophores were from Thermo Fisher Scientific and conjugated to Alexa Fluor 488, 555 and 647. Confocal laser scanning microscopy was performed with an LSM510 (ZEISS) coupled to an Axiovert200M microscope, as previously described (Fernández-Martín et al., 2012). In brief, we used 40×/1.3 oil Plan-Neofluar objective for morphological studies and 63×/1.4 oil Plan-Apochromat and 100×/1.3 oil Plan-Neofluar objectives, for image acquisition of subcellular structures. Acquisition software (LSM510 4.2) was obtained from ZEISS. Quantification of β-catenin and F-actin intensity were performed in ImageJ previous background subtraction. To quantify cell area, images of subconfluent cells stained for F-actin were taken. Quantification of Rac-cherry localization was also performed in ImageJ. In brief, images of subconfluent cells transfected for Rac1-cherry and stained for F-actin were selected. Applying a threshold, a region containing the cell area was automatically created, then made 5 to 10 pixels smaller and subtracted from the original region to generate a region comprising the fluorescence intensity at cell periphery. The main pixels intensity of Rac1-cherry images included in this peripheral region was quantified and compared with fluorescence intensity from the whole cellular area. To generate the mask marking empty spaces within a cell monolayer, a threshold to identify dark spaces was created and subsequently colored and flattened to the original image.
Time-lapse microscopy was performed with an Axiovert200 (ZEISS) microscope, in an environmental chamber at 37°C. A total of 20 mM Hepes, pH 7.4, was added to the culture medium 2 h before the experiment. Images were taken with a cooled CCD camera (Orca-ER C4742-95; Hamamatsu). Camera and shutter (Lambda Instruments) were controlled by Andor Q software. Movies were processed with ImageJ software. Vesicle tracking analysis was performed with ImageJ plugin MTrack2 and Chemotaxis and migration tool software from IBIDI.
Superresolution confocal microscopy
For stochastic optical reconstruction microscopy (STORM), cells were plated in ibiTreat, 35-mm-diameter μ-dishes from IBIDI for 24 h, starved during 1 h, pretreated with TNF, and stimulated with thrombin when indicated. Immunofluorescence was performed as described for confocal microscopy, diluting antibodies with PBS and using the 647N-atto fluorophore for the secondary antibodies. Before laser scanning, cells were washed once with distilled water and then the buffer for STORM microscopy was added (10 mM Tris, pH 8.0, 2 mM NaCl, 2% glucose, 150 mM cysteamine, 60 mM glucose oxidase, and 2 mM cyclooctatetraene). Superresolution microscopy was performed on an Eclipse Ti-E Inverted (Nikon) with an Andor Ixon camera and NIS Elements AR software, using highly inclined illumination. Superresolution images were processed with the ImageJ plugin quickPALM. The analysis of particles clustering was performed using Ripley’s K-function (Kiskowski et al., 2009) programmed in C++. Stimulated emission depletion (STED) superresolution microscopy was performed on a TCS SP5 II STED microscope (Leica Biosystems), with STED being used to detect fluorescence from the ATTO-647N fluorophore. Excitation was performed using a 635-nm pulsed diode laser and de-excitation by a MaiTai tunable fs laser at 750 nm. Superresolution images are presented in inverted grayscale for a clear display of features.
The immunohistochemical analysis of human tissues was approved by the hospital ethics committees of the Hospital Universitario Central de Asturias and the Hospital Universitario de Salamanca were performed as described (Reglero-Real et al., 2014). In addition to biopsies from the mentioned pathologies, controls corresponded to healthy donors or to unaffected tissue of livers or intestine resected from patients with carcinoma. Formalin-fixed, paraffin-embedded sections of 4-µm thickness were deparaffinized in xylene and rehydrated through a decreasing graded-ethanol solution series. After suppression of endogenous peroxidase activity (3% hydrogen peroxide, 10 min) and antigen retrieval (boiling in 10 mM citrate buffer, pH 6.0), immunostaining was performed with a mouse monoclonal antibody against human RhoB from Santa Cruz Biotechnology, Inc. (clone C-5). Isotype-specific control was performed with anti–cytokeratin-7 from Novocastra. Anti-proteoglycan NG2 (Santa Cruz Biotechnology, Inc.) and anti–smooth muscle actin (Santa Cruz Biotechnology, Inc.) were used to identify postcapillary venules. Staining was done by using the Envision Plus peroxidase mouse system (Dako). The stained protein was visualized using DAB solution (Dako) and lightly counterstained with Mayers-hematoxylin. To ascertain the specificity of the antibody immunoreactivity, a negative control was performed in the absence of the primary antibody. In this case, no immunolabeling was detected. Immunohistochemistry was also performed on a fully automated system (Bond III; Leica Biosystems).
Online supplemental material
Fig. S1 shows changes in RhoA, RhoB, and RhoC expression in HDMECs and various cell lines. The screening of expression changes in response to TNF for the rest of the Rho GTPase family members. Fig. S2 shows the specific localization of RhoB expression in intestine fissures in intestines with Crohn’s disease and controls of the immunohistochemical analysis. Fig. S3 shows a full analysis of the compensatory effects of silencing individual or pairs of RhoA subfamily GTPases. Fig. S4 shows the effect of siRhoA, siRhoB, and siRhoC on F-actin levels, adherens junction morphology, and lymphocyte transendothelial migration in TNF-stimulated HUVECs. Fig. S5 shows the lack of colocalization between endogenous RhoB and GFP-Rab4, GFP-Rab11, and endogenous EHD-1 in HUVECs and the colocalization of endogenous RhoB with cherry-Rac1 in HDMVECs. It also shows the biotynilation of Rac-GFP by RhoB-BirA in pull-down assays with neutravidin. It also shows the effect of brefeldin A on the movement of Rac1-Cherry–positive vesicles. Table S1 summarizes the RhoB expression levels detected in various human tissues. Table S2 shows the primers for qPCR analyses. Videos 1 and 2 show the effect of thrombin on GFP-RhoB intracellular trafficking in TNF-pretreated HUVECs. Videos 3 and 4 show the effect of thrombin on cherry-Rac1 intracellular trafficking in TNF-pretreated HUVECs. Videos 5 and 6 show the effect of brefeldin A on cherry-Rac1 trafficking in TNF-pretreated, thrombin-stimulated HUVECs. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201504038/DC1. Additional data are available in the JCB DataViewer at http://dx.doi.org/10.1083/jcb.201504038.dv.
The expert technical advice of the Confocal Microscopy Facility, the Genomic Facility, and Dr. J. Satrústegui and L. Contreras at the Centro de Biología Molecular Severo Ochoa, Madrid, are gratefully acknowledged. The Biobank from Hospital Universitario Central de Asturias, Oviedo, is also acknowledged.
This work supported by Ministerio de Economía y Competitividad grants SAF2014-57950-R (to J. Millán), BFU2015–67266-R (to M.A. Alonso), and BFU2011-22859 (to I. Correas); Comunidad Madrid grant S2010/BMD-2305; and Cancer Research UK (A.J. Ridley). M.C. Ortega and S. Barroso are supported by Endocornea, convenio colaboración Consejo Superior de Investigaciones Científicas, from Instituto Investigaciones Sanitarias Fundación Jiménez Díaz. B. Marcos-Ramiro and D. García-Weber are recipients of a Foreign Policy Initiative fellowship from Ministerio de Economía y Competitividad.
The authors declare no competing financial interests.
- Abbreviations used in this paper:
- dominant negative
- focal adhesion
- human dermal microvascular endothelial cell
- hepatic growth factor
- human umbilical vein endothelial cell
- myosin light chain
- Rho kinase
- stimulated emission depletion
- stochastic optical reconstruction microscopy
- transendothelial electric resistance
- Submitted: 8 April 2015
- Accepted: 13 April 2016
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).